Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study.
Journal: The lancet. Diabetes & endocrinology
Published: June 11, 2025
Relacorilant or surgery improved hemostatic markers in Cushing syndrome.
Journal: Journal of endocrinological investigation
Published: April 19, 2024
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: August 14, 2023
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: August 24, 2022
Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Journal: Frontiers in endocrinology
Published: March 18, 2022
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Journal: Frontiers in endocrinology
Published: October 11, 2021
Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism.
Journal: AACE clinical case reports
Published: April 30, 2021
Evaluation of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent Cushing syndrome.
Journal: Journal of clinical & translational endocrinology
Published: February 16, 2021
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Journal: Frontiers in endocrinology
Published: February 01, 2021
Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.
Journal: Biologics : targets & therapy
Published: December 20, 2017
Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate.
Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
Published: November 29, 2017
Last Updated: 09/26/2026